ACOG Alpha Cognition Inc
- 0.650
- +0.050+8.33%
Alpha Cognition Inc News
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL for Mild to Moderate Alzheimer's Disease
Express News | Alpha Cognition Inc - Received Indications of Interest From Parties Wanting to Provide Bridge Funding
Express News | Alpha Cognition Inc - Has Chosen to Explore Alternative Strategies
Express News | Alpha Cognition Inc - Decision to Temporarily Delay Its Planned Capital Raise and Uplisting to Nasdaq Capital Market
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Alpha Cognition's Oral Therapy ZUNVEYL Receives FDA Approval to Treat Alzheimer's Disease
Alpha Cognition Inc Price Target Raised to C$2.00/Share From C$1.00 by Raymond James
Express News | Alpha Cognition Inc Says Applied to List Common Shares on Nasdaq Under Trading Symbol “Acog”
Press Release: Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
Alpha Cognition Provides Business Update
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of The...
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
Alpha Cognition Reports Amended Terms of Private Placement, Continuation of the Offering
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Canadian Securities Exchange Reports May 2023 Performance Figures
CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)
